FindTrial
Sign In

Genetic response to Covid-19 infection

A prospective, non-randomised observational study to identify immunological and inflammatory response of the host immune genes to Covid-19 infection.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037036
Enrollment
8
Registered
2021-10-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: U07-U07- Provisional assignment of new diseases of uncertain etiology or emergency use

Interventions

None listed

Sponsors

Cancyte Technologies Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients who can read and understand English and given their informed consent gave Informed Consent for the study Covid-19 RT-PCR positive patients Non-Vaccinated , Non-infected , asymptomatic and symptomatic volunteers - (Control Group)

Exclusion criteria

Exclusion criteria: Patient who have not given consent for this study Pregnancy People with the history of Cancer

Design outcomes

Primary

MeasureTime frame
To identify immunological and inflammatory response of the host immune genes to Covid-19 infection.Timepoint: 2 Time points; Day 0 and Day 14—

Secondary

MeasureTime frame
To see the percentage change in immune and inflammatory gene panel selected for the study against controls.Timepoint: 2 Time points; Day 0 and Day 14—

Countries

India

Contacts

Public ContactSudarson Sundarrajan

CANCYTE TECHNOLOGIES PRIVATE LIMITED

sudarson@cancyte.com9738539775

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026